Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label

Last updated: May 13, 2026
Sponsor: Stanford University
Overall Status: Active - Enrolling

Phase

2/3

Condition

Asperger's Disorder

Autism Spectrum Disorder (Asd)

Williams Syndrome

Treatment

N-acetylcysteine

Clinical Study ID

NCT05494398
IRB-64292
K99HD101702
  • Ages 3-13
  • All Genders

Study Summary

The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC and the effects of NAC on altering restricted and repetitive behavior symptom severity in children with autism spectrum disorder.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • participation in an associated single-dose (IRB-54931, NCT04278898) or randomized,controlled trial of NAC (IRB- 68353, NCT05664789).

  • stable medication regimens (≥ 30 days) with no anticipated changes during the trial.

Exclusion

Exclusion criteria:

• the presence of significant medical problems that reduce medical stability.

Study Design

Total Participants: 144
Treatment Group(s): 1
Primary Treatment: N-acetylcysteine
Phase: 2/3
Study Start date:
March 12, 2024
Estimated Completion Date:
January 31, 2029

Connect with a study center

  • Stanford University School of Medicine

    Stanford, California 94305
    United States

    Site Not Available

  • Stanford University School of Medicine

    Stanford 5398563, California 5332921 94305
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.